Learn how semaglutide boosts health but also increases health care spending for patients. Keep reading to explore more.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken off-label for weight loss.

An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...

Oral semaglutide became the first FDA-approved GLP-1RA in tablet form for the treatment of T2D in September 2019, 3,4 and it is now approved in the European Union, United Kingdom, and Japan. 5,6 ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, raising questions about muscle strength and organ size after significant weight loss. University ...

As semaglutide sees a surge in use, new research raises questions about the medication’s effects on muscle health. A study published Aug. 5 in Cell Metabolism and led by researchers at Salt Lake ...

Loss Drug to Irreversible Blindness A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...